National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Daratumumab (Darzalex®)

Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.

Rapid Review

Commenced Completed Outcome
31/05/2016 14/06/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/10/2016  13/03/2017 The cost effectiveness of daratumumab  (Darzalex®) monotherapy  has not been demonstrated. Therefore it is not recommended for reimbursement.

Daratumumab Summary

The HSE has approved reimbursement following confidential price negotiations; April 2018.